J Lamarck SpA
Business Services · Italy · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Via Anelli 28, Desenzano del Garda, Lomb...Website
www.lamarck.comRevenue
<$5 MillionIndustry
About J Lamarck SpA
Is J Lamarck SpA your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
J Lamarck SpA, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when J Lamarck SpA launches new products
Funding: Get notified immidiatlly once J Lamarck SpA has new funding data
Congratulate Masked Content for being promoted to Masked Content at J Lamarck SpA
Website visits: Recent activity has been detected on your website
Check out if J Lamarck SpA is spiking on competitors!
Check if J Lamarck SpA has recently received funding, and reach out quickly before it becomes old news!
Click to see if J Lamarck SpA had a recent Job posting/layoffs
Earning: See what the market has to say on J Lamarck SpA recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined J Lamarck SpA as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
J Lamarck SpA is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
J Lamarck SpA is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about J Lamarck SpA.
J Lamarck SpA Tech Stack
A closer look at the technologies used by J Lamarck SpA
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding J Lamarck SpA
J. Lamarck S.p.A. is a financial consulting firm specializing in biotechnology investments. The company focuses on the strategic implications of biotechnologies, which are projected to significantly impact the global economy by 2030. Their services cater to clients interested in the biopharmaceutical sector, where biotech-derived drugs are already... Read More